Dalpiciclib for hormone receptor–positive advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older, and you’re able to meet the trial’s hormone-status rules (postmenopausal, or pre/peri-menopausal with a hormone-blocking shot during the study).
- Your breast cancer tests positive for hormone receptors, and it has focal recurrence or metastasis that can’t be treated with curative surgery or radiation.
- Your overall health allows treatment (ECOG performance status 0 to 2).
- If you can become pregnant: you must have a negative pregnancy test within 28 days and use highly effective birth control during the study and for 1 year after the last dose; you must not be pregnant or breastfeeding.
- You may not be in another treatment trial at the same time, and you must be willing to follow study visits, labs, and treatment plan.
- You must not have major uncontrolled illnesses (like uncontrolled blood pressure, serious active infection such as hepatitis B/C or HIV, or significant liver/kidney problems), and you must not have had serious side effects (CTCAE grade 3 or higher) from prior treatment that haven’t improved yet.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of three drugs (dalpiciclib, entinostat, and letrozole) for women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. It aims to see if adding these medications before surgery can help shrink the tumor.
This trial tests a new combination of oral hormone therapy (an aromatase inhibitor) plus a CDK4/6 inhibitor (dalpiciclib) for women with early-stage but locally advanced (Stage II–III) hormone receptor-positive, HER2-negative breast cancer. The goal is to shrink the tumor before surgery, potentially improving outcomes.
This trial tests whether a combination of two pills (dalpiciclib and letrozole) can help maintain control of hormone-receptor-positive, HER2-negative breast cancer after initial chemotherapy. It is for people whose cancer has spread or returned and who have not been on an oral CDK4/6 inhibitor before.
This trial tests whether combining brain radiation therapy with two medications—dalpiciclib (a cell-cycle inhibitor) and hormone therapy—can help women with hormone-receptor-positive breast cancer that has spread to the brain. The goal is to shrink brain tumors and improve outcomes.
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
This study tests whether combining two drugs (dalpiciclib and SHR-A1811) before surgery can shrink early-stage breast cancers that are hormone-sensitive and HER2-low. The goal is to see if this approach improves outcomes for patients with intermediate-to-high risk disease.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.